Physician profile
David B Wheeler
NPI 1013008416
$2,116.72
in general payments reported to CMS, 2019-2025
28 companies · $306 in 2025
The $306 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $173 · 2021: $234 · 2022: $507 · 2023: $490 · 2024: $152 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $933 · Education: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $932.87 |
| Education | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $256.11 | 2019-2024 | Mavenclad |
| Ucb, INC. | $224.84 | 2019-2025 | Briviact, Rystiggo |
| Abbvie INC. | $204.04 | 2022-2025 | |
| Sk Life Science, INC. | $201.88 | 2020-2023 | |
| Eisai INC. | $191.44 | 2019-2021 | |
| Abbott Laboratories | $149.94 | 2019-2025 | Infinity |
| Neurelis, INC. | $107.05 | 2020-2022 | |
| Argenx US, INC. | $92.70 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Greenwich Biosciences, INC. | $73.64 | 2020-2021 | |
| Lundbeck LLC | $64.70 | 2020-2022 | |
| Neuropace, INC. | $59.41 | 2022-2025 | |
| Averitas Pharma INC. | $55.48 | 2024-2025 | Qutenza |
| Jazz Pharmaceuticals INC. | $55.20 | 2023 | |
| Pfizer INC. | $53.63 | 2025 | |
| Cognoa, INC. | $50.00 | 2023 | Canvas Dx |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $36.53 | 2022-2023 | Ultomiris |
| Livanova USA, INC. | $35.65 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Genentech USA, INC. | $34.48 | 2020-2021 | |
| Tg Therapeutics, INC. | $28.84 | 2025 | |
| Amgen INC. | $21.81 | 2023 | Aimovig |
| Novartis Pharmaceuticals Corporation | $21.63 | 2022 | |
| Amneal Pharmaceuticals LLC | $20.88 | 2025 | Crexont |
| Allergan, INC. | $15.75 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.23 | 2021 | |
| Biogen, INC. | $13.63 | 2019 | |
| Sunovion Pharmaceuticals INC. | $13.38 | 2021 | |
| Alnylam Pharmaceuticals INC. | $11.20 | 2019 | |
| Travere Therapeutics, INC. | $8.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wheeler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.